OncoLaB is a deep tech biotech venture developing ANGel, a precision drug formulation and delivery platform that simultaneously enhances targetability, efficacy, and sustainability of cancer therapeutics.
Founded in May 2024 by Dr. Jongseong Kim—an expert with over 20 years of experience in bioadaptive nanogel and immunology research—OncoLaB has since achieved the following milestones:
- Secured $500K seed investment
- Selected for the Deep Tech TIPS program by the Ministry of SMEs and Startups ($1.5M in funding)
- Awarded a TIPS follow-up grant ($200K in funding)
Starting with triple-negative breast cancer (TNBC), OncoLaB is rapidly growing as a precision oncology platform company, expanding its indications to other intractable solid tumors such as prostate cancer.
What Makes ANGel Different
ANGel is a next-generation platform that modularizes and reformulates approved anti-cancer drugs to deliver them precisely to tumor tissues.
- Precision Targeting: Locally injectable formulation designed to accumulate at high concentrations near tumors
- Sustained Release: One-time administration enables long-term therapeutic effect
- Immuno-synergistic Activation: Maximizes efficacy by combining chemotherapy and immunoactivation
ANGel is not just a drug delivery system—it is a transformative cancer treatment solution designed to improve quality of life and increase survival.
Strategic Response to the Global Patent Cliff
ANGel is strategically designed to address the global patent cliff for immune-oncology drug formulations anticipated from 2028. By integrating existing anti-cancer drugs into the ANGel platform, we generate significant value:
- Enhancing efficacy and minimizing toxicity of existing drugs
- Building new pipelines through drug reformulation
- Enabling out-licensing opportunities to global pharmaceutical companies
Open Innovation, Collaborative Growth
OncoLaB embraces open innovation by working closely with internal experts and external partners to accelerate development. We drive a paradigm shift in cancer therapy through:
- Compatibility with a wide range of anti-cancer agents
- Global co-development and bio-partnering opportunities
- Pipeline expansion via our modular platform strategy
Our Vision for the Future
OncoLaB is committed to transcending the limitations of conventional cancer therapies—minimizing side effects, maximizing efficacy, and building a platform that protects the lives of patients and their loved ones.